BioAtla Investor Presentation Deck

Phase 1 CAB-CTLA-4 (BA3071): Demographics - Tumor Types All patients experienced failure of prior PD1 treatment Tumor Type Cervical Gastric Melanoma Uveal Cutaneous Renal cell Urothelial NSCLC SCLC Pt - Platinum; Data Cut Date: 15Nov23 bicatla Total (N=18) 1 (5.6) 4 (22.2) 5 (27.8) 3 (16.7) 2 (11.1) 4 (22.2) 1 (5.6) 2 (11.1) 1 (5.6) Prior Number of Tx 3 4-6 1-2 1-6 4 3-7 3 Prior Treatment pt, anti-VEGF, anti-PD1 anti-PD1 and pt chemotherapies anti-PD1 prior anti-PD1 and TKI pt chemotherapies, anti-PD1 and ADC pt chemotherapies, taxanes, anti-PD1, TKI, anti-VEGF pt chemotherapies, anti-PD1 BioAtla| Overview 14

View entire presentation